Nanjing Medlander Medical Technology Co (SHSE:688273) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nanjing Medlander Medical Technology Co EBITDA Margin % Related Terms
Nanjing Medlander Medical Technology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Medlander Medical Technology Co EBITDA Margin % Chart
Nanjing Medlander Medical Technology Co Annual Data
SHSE:688273 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Nanjing Medlander Medical Technology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Medlander Medical Technology Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanjing Medlander Medical Technology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nanjing Medlander Medical Technology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Medlander Medical Technology Co (SHSE:688273) has a EBITDA Margin % of 24.33% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nanjing Medlander Medical Technology Co and its competitors. This is 42% below median its historical median of 42.00. Over the past decade, Nanjing Medlander Medical Technology Co's EBITDA Margin % has ranged from 21.44 to 47.23. According to the industry distribution chart, Nanjing Medlander Medical Technology Co ranks #178 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 21.8%.
Is Nanjing Medlander Medical Technology Co's EBITDA Margin % too high?
Nanjing Medlander Medical Technology Co's current EBITDA Margin % of 24.33% is 42% below median its 10-year median of 42.00. Over the past 10 years, this metric has ranged from a low of 21.44 to a high of 47.23. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. Nanjing Medlander Medical Technology Co's value of 24.33% is 227% above this industry median. Based on the distribution chart, Nanjing Medlander Medical Technology Co ranks #178 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nanjing Medlander Medical Technology Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Medlander Medical Technology Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nanjing Medlander Medical Technology Co ranks #178 out of 817 companies for EBITDA Margin %. This places Nanjing Medlander Medical Technology Co in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.44. Nanjing Medlander Medical Technology Co's value of 24.33% is 227% above this benchmark. Historically, Nanjing Medlander Medical Technology Co's own EBITDA Margin % has ranged from 21.44 to 47.23 over the past decade. While the company's 10-year median is 42.00 vs. the industry median of 7.44, Nanjing Medlander Medical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Medlander Medical Technology Co's current EBITDA Margin % of 24.33% is 227% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nanjing Medlander Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Medlander Medical Technology Co's current EBITDA Margin % is 24.33%, which is 42% below median its own 10-year median of 42.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Medlander Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co (SHSE:688273) is currently considered Fairly Valued. The stock's GF Value™ is ¥34.49, compared to a current price of ¥36.77 — trading 6.6% above its estimated fair value. The current EBITDA Margin % is 24.33%, which is 42% below median its 10-year median of 42.00 and 227% above the Medical Devices & Instruments industry median of 7.44. Nanjing Medlander Medical Technology Co's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nanjing Medlander Medical Technology Co (SHSE:688273), the current EBITDA Margin % is 24.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Medlander Medical Technology Co (SHSE:688273) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co stock appears to be overvalued.
The current stock price of ¥36.77 is trading 6.6% above its estimated GF Value™ of ¥34.49.
GuruFocus considers Nanjing Medlander Medical Technology Co to be Fairly Valued.
Key valuation signals for SHSE:688273:
EBITDA Margin %: 24.33% (42% below median its 10-year median of 42.00)
GF Value™: ¥34.49 vs. price of ¥36.77 (6.6% above fair value)
Industry Position: 227% above the Medical Devices & Instruments median (#178 of 817)
No single metric tells the full story. See the SHSE:688273 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanjing Medlander Medical Technology Co Business Description
Nanjing Medlander Medical Technology Co Ltd is engaged in the research and development, production, sales, and service of related products in the field of pelvic floor and postpartum rehabilitation. Its products mainly include: biostimulation feedback instrument, color ultrasound diagnosis and evaluation system, magnetic stimulator, high-frequency evaluation electrocautery instrument, pelvic floor training instrument, portable postpartum recovery instrument, home pelvic floor rehabilitation therapy instrument, etc., which are widely used in obstetrics and gynecology, pelvic floor rehabilitation center, urology, anorectal department and other hospital departments.
82GF Score
Get the complete analysis for SHSE:688273
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688273 has been successfully added to your 
